Immunome Reports $53.8 Million Net Loss in Q1 2026, Cash Reserves Decline

Immunome, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $53.8 million, an increase from a net loss of $41.6 million in the same period last year. The company's total operating expenses rose to $59.3 million, up from $47.6 million in the prior year, primarily driven by increased research and development costs, which climbed to $46.4 million from $36.9 million. The company did not generate any collaboration revenue during the quarter, a decrease from $2.9 million reported in the first quarter of 2025, as the collaboration agreement with AbbVie concluded in July 2025.

The company's cash and cash equivalents stood at $582.7 million as of March 31, 2026, down from $653.5 million at the end of 2025. This decline was attributed to cash used in operating activities, which totaled $58.6 million for the quarter, compared to $53.1 million in the same period last year. The increase in cash used was largely due to the higher net loss and changes in operating assets and liabilities. The company’s accumulated deficit reached $782.0 million, reflecting its ongoing investment in research and development without generating product revenue.

Immunome has been actively advancing its clinical pipeline, which includes four clinical assets and two preclinical assets. The lead candidate, varegacestat, is under evaluation for the treatment of desmoid tumors, with a new drug application submitted in April 2026. The company also initiated a Phase 1 trial for IM-3050, a radioligand therapy targeting solid tumors, and plans to start trials for IM-1617, a first-in-class antibody-drug conjugate, in the second quarter of 2026. The company’s strategic focus remains on developing targeted oncology therapies, leveraging its proprietary technologies and collaborations.

In terms of operational metrics, Immunome's employee headcount has increased, contributing to higher general and administrative expenses, which rose to $13.0 million from $10.7 million year-over-year. The increase in personnel-related costs, including share-based compensation, was a significant factor in this rise. The company continues to explore additional funding avenues to support its ongoing research and development efforts, indicating that it may need to raise additional capital through equity offerings or strategic partnerships in the future.

Looking ahead, Immunome expects its existing cash reserves to fund operations for at least the next 12 months. However, the company acknowledges the need for additional financing to support its research and development strategy and the potential commercialization of its product candidates. The management remains focused on advancing its clinical programs while navigating the challenges inherent in the biotechnology sector, including regulatory approvals and market conditions.